DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Plecanatide
Plecanatide
Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
Guts and Butts: Treatment Options for IBS and Functional Dyspepsia
New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety
Preferred Drug List 4-Tier
Therapeutically Targeting Guanylate
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Update on the Management of Constipation
Current and Emerging Concepts in Irritable Bowel Syndrome
Functional Bowel Disease
Update on Pharmacotherapy for Irritable Bowel Syndrome
TRULANCE Safely and Effectively
Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins
VA/Dod CLINICAL PRACTICE GUIDELINE for the MANAGEMENT of CHRONIC MULTISYMPTOM ILLNESS
The POTS (Postural Tachycardia Syndrome) Epidemic: Hydration and Nutrition Issues
Therapeutic Class Overview
Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects Of
Top View
TRULANCE (Plecanatide) Tablets, for Oral Use • for Patients Who Have Difficulty Swallowing Tablets Whole Or Initial U.S
Prescription Drug List an Evidence-Based Pharmacy Program That Works for You
Gastroenterology
Profile of Plecanatide in the Treatment of Chronic Idiopathic Constipation: Design, Development, and Place in Therapy
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
Trulance) Reference Number: ERX.NPA.05 Effective Date: 06.01.17 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log
Wireless Capsule Motility Test Smartpilltm Preparation Instructions
Current Status of Selected Oral Peptide Technologies in Advanced Preclinical Development and in Clinical Trials TA Aguirre
California 3 Tier with Specialty Drug List
Amyloidosis & The
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Up-To-Date Diagnosis and Management of IBS and Chronic Constipation in Primary Care
Chronic GI Motility Agents Medical Policy No
Trulance) Reference Number: CP.PMN.87 Effective Date: 02.01.17 Last Review Date: 11.20 Line of Business: Commercial, HIM, Medicaid Revision Log
TARGETING CYCLIC GMP SIGNALING for the TREATMENT of GASTROINTESTINAL DISEASES by October COPYRIGHT© 2017 by Sarah Sharman
WO 2014/197720 A2 11 December 2014 (11.12.2014) P O P CT
Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
Changes Highlighted Final Version Date of Issue
Key Potentially Inappropriate Drugs in Pediatrics
Irritable Bowel Syndrome
IBS-Monograph-2018.Pdf
Prucalopride for the Treatment of Chronic Idiopathic Constipation FDA Advisory Committee Meeting Briefing Document Gastrointesti
Pharmacotherapy for Irritable Bowel Syndrome
Quantity Limits — Select
FDA Briefing Document JOINT MEETING of THE
NH Healthy Families Pharmacy & Therapeutics Committee 20Q4 Combined Guideline Summary
Management of Irritable Bowel Syndrome
Paragraph IV Patent Certifications (PPIV)
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Current Overview on Clinical Management of Chronic Constipation
Klasifikacija ATC 2021
Irritable Bowel Syndrome
Medicines Regulation
Gut Instincts: Gi Symptom Management
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Guanylate Cyclase-C As a Therapeutic Target in Gastrointestinal Disorders
Digestivehealth Matters Participate in Your Own Health Care | Vol
FDA Briefing Document Gastrointestinal Drug Advisory Committee Meeting